Search Result

Results for "

cancer immunotherapy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Anaplastic lymphoma kinase (ALK) (1) c-Kit (2) CD73 (1) Checkpoint Kinase (Chk) (1) CTLA-4 (1) Discoidin Domain Receptor (2) Endogenous Metabolite (5) FLT3 (3) HDAC (1) IFNAR (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Ligands for Target Protein for PROTAC (1) MAP4K (2) PD-1/PD-L1 (4) Phosphatase (1) Prostaglandin Receptor (1) PROTACs (1) ROR (1) STING (7) TAM Receptor (1) Toll-like Receptor (TLR) (3) Trk Receptor (2) VEGFR (2)
By Research Areas:	Cancer (39) Inflammation/Immunology (16) Neurological Disease (1)

By Targets:

Adenosine Receptor (1)

Anaplastic lymphoma kinase (ALK) (1)

c-Kit (2)

CD73 (1)

Checkpoint Kinase (Chk) (1)

CTLA-4 (1)

Discoidin Domain Receptor (2)

Endogenous Metabolite (5)

FLT3 (3)

HDAC (1)

IFNAR (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Ligands for Target Protein for PROTAC (1)

MAP4K (2)

PD-1/PD-L1 (4)

Phosphatase (1)

Prostaglandin Receptor (1)

PROTACs (1)

ROR (1)

STING (7)

TAM Receptor (1)

Toll-like Receptor (TLR) (3)

Trk Receptor (2)

VEGFR (2)

By Research Areas:

Cancer (39)

Inflammation/Immunology (16)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-133123

EP4 receptor antagonist 1	Prostaglandin Receptor	Inflammation/Immunology Cancer
EP4 receptor antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist for cancer immunotherapy. EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC₅₀s of 6.1 nM and 16.2 nM, respectively. IC₅₀s >10 μM for human EP1, EP2,and EP3 receptors .

HY-163041

PD-1/PD-L1-IN-36	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-36 (Compound 2k) is a PD-1/PD-L1 complex inhibitor (IC₅₀: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy .

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC₅₀ of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy .

HY-149520

HPK1-IN-39	MAP4K	Cancer
HPK1-IN-39 (Compound 10n) is a selective HPK1 Inhibitor (IC₅₀: 29 nM). HPK1-IN-39 inhibits the phosphorylation of SLP76. HPK1-IN-39 can be used for research of cancer immunotherapy .

HY-155675

TPPC

Others Cancer

TPPC, a porphyrin cholesterol conjugate, can render cancer cells more sensitive to ICIs. TPPC can enhance photodynamic immunotherapy toward lung cancer .

TPPC	Others	Cancer
TPPC, a porphyrin cholesterol conjugate, can render cancer cells more sensitive to ICIs. TPPC can enhance photodynamic immunotherapy toward lung cancer .

HY-153544

TLR7/8 agonist 9	Toll-like Receptor (TLR)	Cancer
TLR7/8 agonist 9 (Compound 25a) is a TLR7/8 agonist, with EC₅₀s of 40 nM and 23 nM for hTLR7/8. TLR7/8 agonist 9 has anti-tumor activity and improves the antitumor activity of PD-1/PD-L1 blockade. TLR7/8 agonist 9 can be used for research of cancer immunotherapy .

HY-146231A

SS47 TFA	MAP4K PROTACs	Inflammation/Immunology Cancer
SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies . SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-160151

TP1L

Ligands for Target Protein for PROTAC Cancer

TP1L is a selective TC-PTP PROTAC degrader for cancer immunotherapy with a DC50 value of 35.8 nM .

TP1L	Ligands for Target Protein for PROTAC	Cancer
TP1L is a selective TC-PTP PROTAC degrader for *cancer* immunotherapy with a DC50 value of 35.8 nM .

HY-P9902

Pembrolizumab Maximum Cited Publications 9 Publications Verification MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-33299

Serpin B9-IN-1 BTCA	Others	Others
Serpin B9-IN-1 (BTCA), a specific SB9-targeted inhibitor, significantly inhibits immunotherapy of lung cancer bone metastases in CA mouse models (LCBM).

HY-144072

MRS4620

CD73 Inflammation/Immunology Cancer

MRS4620 is a potent CD73 inhibitor, with a K_i of 0.436 nM. MRS4620 can be use for the research of cancer immunoresearch .

MRS4620	CD73	Inflammation/Immunology Cancer
MRS4620 is a potent CD73 inhibitor, with a K_i of 0.436 nM. MRS4620 can be use for the research of cancer immunoresearch .

HY-108681

680C91	Others	Neurological Disease Inflammation/Immunology Cancer
680C91 is an orally active, selective tryptophan 2,3-dioxygenase (TDO) inhibitor with a K_i of 51 nM. TDO is the key enzyme of tryptophan catabolism. 680C91 can be used for the research of cancer immunotherapy and Alzheimer’s Disease .

HY-130607

IDO1-IN-2	Indoleamine 2,3-Dioxygenase (IDO)	Inflammation/Immunology Cancer
IDO1-IN-2 (compound 16) is a potent and selective IDO1 inhibitor with IC₅₀s of 81 nM, 59 nM (mouse) and 28 nM (rat), respectively. IDO1-IN-2 has anti-cancer activity .

HY-N1420A

Rhamnose monohydrate L-Rhamnose monohydrate	Endogenous Metabolite	Cancer
Rhamnose monohydrate (L-Rhamnose monohydrate) is a monosaccharide found in plants and bacteria. Rhamnose monohydrate-conjugated immunogens is used in immunotherapies . Rhamnose monohydrate crosses the epithelia via the transcellular pathway and acts as a marker of intestinal absorption .

HY-126321

RORγt agonist 1	ROR	Cancer
RORγt agonist 1 (compound 14) is a potent, orally bioavailable RORγt agonist with an EC₅₀ of 20.8 nM. RORγt agonist 1 showes high metabolic stability, improved aqueous solubility and excellent mouse PK profile. RORγt agonist 1 is a potential candidate of RORγt agonist for cancer immunotherapy .

HY-154919

DC-Y13-27 2 Publications Verification	Others	Cancer
DC-Y13-27, a derivative of DC-Y13, is a YTHDF2 inhibitor (K_D: 37.9 μM). DC-Y13-27 enhances tumor responses to radiotherapy and immunotherapy .

HY-111786

LHC-165

Toll-like Receptor (TLR) Cancer

LHC-165 is a TLR7 agonist. LHC-165 has potential to used in study of solid tumors .

LHC-165	Toll-like Receptor (TLR)	Cancer
LHC-165 is a TLR7 agonist. LHC-165 has potential to used in study of solid tumors .

HY-155109

Antitumor agent-114	STING	Inflammation/Immunology Cancer
Antitumor agent-114 is a potent stimulator of interferon genes (STING) agonist. Antitumor agent-114 activates immunity and reduces tumor volume in a mouse model of breast cancer. Antitumor agent-114 can be used for immunity and cancer diseases research .

HY-143324

A2AAR/HDAC-IN-1	HDAC Adenosine Receptor	Cancer
A2AAR/HDAC-IN-1 (compound 14c) is an orally active, potent and balanced A_2AAR/HDAC dual inhibitor, with a K_i of 163.5 nM for A_2AAR and an IC₅₀ of 145.3 nM for HDAC1. A2AAR/HDAC-IN-1 shows anticancer activity .

HY-119109

Laminaran	Others	Cancer
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities . Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds . Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy .

HY-155847

LYP-IN-3	Phosphatase	Cancer
LYP-IN-3 (compound D34) is a selective inhibitor of Lymphoid-tyrosine phosphatase (LYP) (Ki=0.93 μM), and regulates T-cell receptor (TCR) signaling pathway in tumor progress. LYP-IN-3 activates T-cell and inhibits M2 macrophage polarization, but upregulates PD-1/PD-L1 expression. LYP-IN-3 can be leveraged with PD-1/PD-L1 inhibitor, for futher cancer immunotherapy .

HY-132200

UNC5293	TAM Receptor Anaplastic lymphoma kinase (ALK) FLT3	Cancer
UNC5293 is a MERTK-selective and potent inhibitor (K_i=190 pM). UNC5293 inhibits MERTK (IC₅₀=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research .

HY-107780

Cyclic-di-GMP c-di-GMP; cyclic diguanylate; 5GP-5GP	STING Endogenous Metabolite	Cancer
Cyclic-di-GMP is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research .

HY-107780A

Cyclic-di-GMP sodium c-di-GMP sodium; cyclic diguanylate sodium; 5GP-5GP sodium	STING Endogenous Metabolite	Cancer
Cyclic-di-GMP sodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP sodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP sodium can be used in cancer research .

HY-107780B

Cyclic-di-GMP diammonium 2 Publications Verification c-di-GMP diammonium; cyclic diguanylate diammonium; 5GP-5GP diammonium	STING Endogenous Metabolite	Cancer
Cyclic-di-GMP diammonium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP diammonium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP diammonium can be used in cancer research .

HY-110382

Cyclic-di-GMP disodium 2 Publications Verification c-di-GMP disodium; cyclic diguanylate disodium; 5GP-5GP disodium	STING Endogenous Metabolite	Cancer
Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research .

HY-P99809

Quavonlimab

MK-1308
CTLA-4 Cancer

Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody .

Quavonlimab MK-1308	CTLA-4	Cancer
Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody .

HY-144501

D18	Toll-like Receptor (TLR) PD-1/PD-L1	Inflammation/Immunology Cancer
D18 is an immune modulator. D18 acts as a TLR7/8 dual agonist (EC₅₀=24 nM for hTLR7 and 10 nM for hTLR8, respectively). D18 increases PD-L1 expression through epigenetic regulation, thus sensitizing tumors to PD-1/PD-L1 blockade. D18 is a ADC cytotoxin uesd for the systhesis of ADC HE-S2 .

HY-P99032

Monalizumab 1 Publications Verification IPH2201	Checkpoint Kinase (Chk) IFNAR	Inflammation/Immunology Cancer
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .

HY-144329

STING agonist-11	STING	Inflammation/Immunology Cancer
STING agonist-11 (Compound 92) is a potent small molecule cyclic urea activator of STING with EC₅₀ of 18 nM. Activation of STING is a highly promising approach in immunotherapy .

HY-144328

STING agonist-10	STING	Inflammation/Immunology Cancer
STING agonist-10 (Compound 91) is a potent small molecule cyclic urea activator of STING with the EC₅₀ of 2600 nM. Activation of STING is a highly promising approach in immunotherapy .

HY-16961

Sitravatinib 1 Publications Verification MGCD516; MG-516	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-16961A

Sitravatinib malate MGCD516 malate; MG-516 malate	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

Cat. No.	Product Name

HY-L079

Anti-Blood Cancer Compound Library	2676 compounds
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 2676 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Anti-Blood Cancer Compound Library

2676 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2676 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L075

Anti-Lung Cancer Compound Library	1835 compounds
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 1835 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Anti-Lung Cancer Compound Library

1835 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 1835 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

HY-L031

Small Molecule Immuno-Oncology Compound Library	486 compounds
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 486 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Small Molecule Immuno-Oncology Compound Library

486 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 486 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

GADGVGKSA	Peptides	Inflammation/Immunology Cancer
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research .

GADGVGKSAL	Peptides	Inflammation/Immunology Cancer
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research .

GAGGVGKSAL	Peptides	Cancer
GAGGVGKSAL is a wild-type KRAS G12D 10mer peptide. GAGGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research .

GAGGVGKSA	Peptides	Inflammation/Immunology Cancer
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research .

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC₅₀ of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy .

PSA1 (141-150) PSA-Peptide	Peptides	Cancer
PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments .

Alrefimotide hTERT (660–689)	Peptides	Cancer
Alrefimotide is a hTERT-derived immunogenic peptide. Alrefimotide has a sequence of ALFSVLNYERARRPGLLGASVLGLDDIHRA. Alrefimotide can be used in **cancer immunotherapy** research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks